Kate Kearney, MD, FSCAI is an Assistant Professor at the University of Washington Medical Center in Seattle, where she completed residency, cardiology and two years of interventional cardiology training after graduating from the University of Pittsburgh Medical School in 2009. She is the director of the brachytherapy program and is the local PI on several device trials. Her clinical practice is focused on high risk PCI including CTO PCI, and she is the Associate Program Director of the interventional cardiology fellowship. Current research interests include patient selection for interventional strategies after out-of-hospital cardiac arrest and hemodynamic support utilization, operator radiation exposure in the cath lab, and care variability.<span class=”Apple-converted-space”> </span>

Dr O’Kane graduated from Charing Cross & Westminster Medical School in 1995 with a First Class Honors Bachelor of Science BSc degree in Physiology, a Medical Degree MBBS and numerous prizes including the Llewelyn Prize for the second-best distinction in medical finals.

After attaining membership of the Royal College of Physicians MRCP, he was subsequently awarded a Doctorate of Medicine MD by the University of London for a thesis on the role of nitric oxide in coronary heart disease.

Dr O’Kane was appointed as Consultant Interventional Cardiologist at the Royal Bournemouth Hospital in July 2007. Working in the UK’s highest volume non-surgical PCI center, he has performed over 6000 PCI procedures as a Consultant operator, and so is one of the highest volume UK operators. He routinely treats extensively calcified lesions, bifurcations including left main stem disease, and chronic total occlusions.

He is committed to teaching and education, from local fellowship training programs to national and international proctorship of techniques and multiple adjunctive devices e.g. rotational and laser atherectomy. Consequently, he has trained Consultant colleagues from the UK, Europe, Asia, and the US. Dr. O’Kane is regularly invited as faculty to national and international meetings as a presenter and live case operator.

He has published over 50 manuscripts in the last 20 years including original work, international collaboration and case studies. He has authored 10 book chapters particularly related to laser atherectomy. He is a local principal investigator for 29 national and international multi-center clinical trials and is dedicated to patient recruitment to studies with over 850 patients recruited into trials he has managed.

Within the Cardiology Directorate, Dr. O’Kane has led numerous quality improvement programs, serves as Cardiology Governance and Mortality Lead, and has achieved Local Clinical Excellence Award Level 7. He is a nationally elected member to the British Cardiovascular Intervention Society (BCIS) Council and Wessex Cardiology representative for the Royal College of Physicians.

Dr. Anbukarasi (Arasi) Maran is an associate professor of medicine in the Division of Cardiology and the director of the Coronary CTO Program at the Medical University of South Carolina and the Ralph H Johnson VA Medical Center.

Dr. Maran completed her medical school training in India. She then did her Internal Medicine, General Cardiology and Interventional Cardiology training at the Medical University of South Carolina, Charleston. She stayed on as faculty at MUSC, where she started the Coronary CTO Program in 2016. Dr. Maran also initiated the Women in Cardiology Program at MUSC to mentor women cardiology fellows and to encourage medical residents to choose cardiology as a subspeciality. She is a strong advocate for women in medicine. Apart from coronary CTO, her clinical interests include CHIP & Mechanical Circulatory support. Dr. Maran is also a mother of three children. Her other interests include reading, working out and spending time with her family.

James Spratt is a Professor of Interventional cardiology with a sub-specialty interest in complex PCI, intravascular imaging, and CTO. He is widely published within this area and has performed live case demonstrations globally. He has an interest in medical education and is the Founder of Optima Education.

Dr. Daniel Chamié is an Interventional Cardiologist at the Dante Pazzanese Institute of Cardiology in Sao Paulo, Brazil. After concluding his Interventional Cardiology training at the same Institution in 2009, Dr. Chamié undertook a research associate position in the Intravascular Imaging Core Laboratory at the University Hospitals Case Medical Center, Cleveland, OH (2010-2012). After returning to Brazil in the end of 2012, he assumed a faculty position as Interventional Cardiologist at the Dante Pazzanese Institute of Cardiology and has served as Director of the OCT Core Laboratory at the Cardiovascular Research Center in Sao Paulo. Over the last eight years Dr. Chamié has conducted core laboratory analysis for numerous OCT studies on various interventional devices (e.g. balloons, metallic stents and bioresorbable scaffolds) and clinical scenarios (e.g. high bleeding risk patients, restenosis, acute coronary syndromes, bifurcation lesions). Dr. Chamié is the leading investigator of the iSIGHT trial, proposing a novel algorithm for OCT-guided PCI, which served as the topic for his PhD from the University of Sao Paulo. His current interests are on complex PCI, application of intravascular imaging and physiology in the context of complex PCI, and development of novel analysis methods for OCT studies.

Dr. Nieves Gonzalo is a Consultant Interventional Cardiologist in the Interventional Cardiology Department at Clinico San Carlos University Hospital in Madrid. She obtained her Specialist Certification in Cardiology after training at the same hospital. Subsequently, she underwent a research fellowship at Thoraxcenter, Erasmus University Rotterdam (The Netherlands) under the supervision of Professor Patrick Serruys, focused mainly in intracoronary imaging and bioabsorbable stents. In 2010 she obtained her PhD with the thesis “Optical coherence tomography for the assessment of coronary atherosclerosis and vessel response after stent implantation.” Her track record includes over 170 articles indexed in PubMed, as well as book chapters in Interventional Cardiology textbooks. Recent research projects as principal investigator include a study about the assessment of neoatherosclerosis and its clinical impact in patients with restenosis, and research regarding vessel injury and healing evaluation with different stent platforms evaluated with OCT. Dr. Gonzalo is a dedicated educationalist with involvement in many areas of complex PCI, serving currently as Deputy Editor for Eurointervention and Committee Member of EuroPCR.

Dr. Dupont is an interventional cardiologist at Northside Hospital Cardiovascular Institute (NCVI) in Atlanta.  She is the medical director of the ECMO program at Northside Hospital System and is passionate about improving outcomes in cardiogenic shock patients.  She has been the local PI for the National Cardiogenic Shock Initiative (NCSI).  Dr. Dupont specializes in high-risk PCI and also performs structural interventions, including percutaneous edge-to-edge mitral valve repair and left atrial appendage occluder implantation.  She serves on the SCAI WIN (Women in Innovations) and Communications committees.

Dr. Tom Johnson has been a consultant at the Bristol Heart Institute for 10 years and holds an honorary contract as Senior Lecturer at the University of Bristol. He is an active member of the EAPCI, sitting on the education & training and scientific programme committees. He is a board member of PCR and the European Bifurcation Club. Dr. Johnson’s interests include education, platelet pharmacology, novel therapies for acute myocardial infarction, intravascular imaging, and bifurcation PCI. He was coordinating author for the European Consensus on Intravascular Imaging Part 2, presented & published in 2019.

Prof. Ernst is a German cardiac electrophysiologist with a special expertise in complex arrhythmias such as atrial fibrillation and ventricular arrhythmia both in pediatric and adult patients. Having studied medicine in Germany, the United States and Switzerland, she worked for 10 years at the St. Georg Hospital in Hamburg, Germany. She obtained her “Habiliation” on catheter ablation techniques for atrial fibrillation in 2005 at the University of Hamburg-Eppendorf. In 2007, she accepted the position of Research Lead Electrophysiology at the Royal Brompton and Harefield NHS Foundation Trust in London and has been a Reader in Cardiology at the National Heart and Lung Institute of Imperial College since 2012. Prof. Ernst is one of the pioneers of remote magnetic navigation and has established this technique from its initiation to clinical routine using state of the art equipment including advanced 3D mapping techniques. Image integration from 3D acquisitions from magnetic resonance imaging or computed tomography assist her in performing her interventions. In particular, patients with congenital heart disease, complex anatomy and drug-refractory arrhythmias are benefiting from these advances and form a major emphasis in Dr. Ernst’s clinical work. She is also a strong advocate for radiation protection measures, which benefits not only her patients, but also the cath lab staff. She performs all of her procedures with low or ZERO fluoroscopy and collaborates with a number of companies to facilitate these interventions.

Besides being well published in peer-reviewed journals, Prof. Ernst published a book on “Anatomy for Cardiac Electrophysiologists” together with Prof. Siew Yen Ho (Cardiac Morphology, Imperial College) in 2012, which is now also available in Chinese. A second volume to this benchmark publication is currently in preparation. She serves on the editorial board of a number of scientific journals (Circulation Arrhythmia and Electrophysiology, Europace, Journal of Interventional Cardiovascular Electrophysiology, Herzschrittmacher, and Elektrophysiologie). She was Associate Editor of “Heart” from 2013-2019 and is now Associate Editor for the International Journal of Cardiology, as well as the sub-journal of Congenital Heart Disease.

In recent years, Prof. Ernst’s research has focused on novel imaging techniques to visualize the autonomic nervous system in order to better understand its role for the initiation and maintenance of cardiac arrhythmia. She has held several posts both in European (ESC & EHRA) and American (HRS) electrophysiology- themed societies and was a board member of EHRA as the Coordinator for Women in Electrophysiology. She is also a founding member of the Electrophysiology International Community (EPIC), a global initiative to promote Women in Electrophysiology active since 2008. Also in 2008, she joined the Executive Board of the British Arrhythmia Patient Charity (Arrhythmia Alliance UK).

Dr. Knight is currently the Chester C. and Deborah M. Cooley Distinguished Professor of Cardiology at Northwestern University, and has been the Director of Cardiac Electrophysiology at the Bluhm Cardiovascular Institute at Northwestern Medicine since November 1, 2009. His clinical interests remain broad and include management of all types of heart rhythm disorders and implantation of cardiac rhythm management devices, but his clinical focus has been on catheter ablation for complex arrhythmias. His research interests include atrial fibrillation, novel tools for catheter ablation, left atrial appendage closure, intracardiac imaging, diagnostic pacing maneuvers in the EP laboratory, extravascular defibrillators, and sudden cardiac arrest.

He earned his Bachelor’s Degree at the University of North Carolina in Chapel Hill in the School of Public Health, and his Medical Degree at the Ohio State University. After completing his training in Medicine, Cardiology, and Cardiac Electrophysiology at the University of Michigan, he joined the Michigan faculty in 1997. He moved to the University of Chicago in 2002 where he was the Director of Cardiac Electrophysiology for seven years. Dr. Knight has been an investigator for several multicenter clinical trials, and is on the editorial board of several major medical journals. He has published over 300 peer-reviewed manuscripts, reviews, case reports, and editorials, and is the Editor-in-Chief of EPLab Digest and Pacing and Cardiac Electrophysiology (PACE).

Dr. Gregory Feld graduated from Dartmouth Medical School in 1977, was an Intern and Resident at the VA Medical Center in West LA and UCLA from 1977 to 1980, Chief Medical Resident at the VA in 1981, and Cardiovascular Diseases fellow in 1982. He received training in Clinical Cardiac Electrophysiology during his CVD fellowship and was subsequently appointed to the faculty of the University of California, Los Angeles in 1984 with a three-year award as Research Associate in Cardiac Electrophysiology at the VA Medical Center. Dr. Feld was subsequently appointed to the faculty at UCSD in 1987 and is currently Professor of Medicine, and Director of Cardiac Electrophysiology and the Cardiac Electrophysiology Fellowship Training program.

Kyoko Soejima is a Professor and Chair of the Department of Cardiovascular Medicine at Kyorin University, Tokyo. She specializes in the management of cardiac arrhythmias and sudden cardiac death prevention, including catheter ablation of complex arrhythmias and device therapy. She earned her medical degree from Keio University School of Medicine.

Cecilia Linde, MD is a professor and consultant in cardiology in the Heart and Vascular Department at the Karolinska University Hospital and the Karolinska Institutet in Stockholm, Sweden. Her research currently focuses on devices and epidemiology in heart failure. She was co-chairman of the MUSTIC study, and principal investigator of the REVERSE study, which was the first to show a benefit of CRT in mild heart failure, and the MIRACLE-EF study focusing on CRT in HFmREF. These studies have all been international and have included Professor Daubert, Rennes University, France as lead or co-lead.  Dr. Linde also chairs the Stockholm PREFERS studies with Associate Professor Hans Persson. PREFERS focuses on epidemiology, imaging, biomarkers in new onset heart failure with special attention to HFpEF, and on the transition from hypertension to heart failure in the search of new drug targets. She is co-PI of the European CRT survey II covering 10.088 CRT implantations across 42 European countries with Professor Kenneth Dickstein, Stavanger, Norway.

Dr. Linde is the author of more than 300 papers, reviews and editorials in a wide variety of fields including CRT, hemodynamic monitoring and HFpEF.  She serves on the editorial board of several journals. Dr. Linde was scientific programme chair for the European Heart Rhythm Association (EHRA) annual meeting from 2013-2015 and has served on many guidelines writing committees of EHRA and Heart Failure Association.  She is Doctor Honoris causa at the University of Rennes and Honorary Member of the Hungarian Cardiac Society in 2017.  Dr. Linde also served as Vice President of the ESC Board from 2018-2020, and served on various committees including working groups, councils, women, the young, and membership.  She was Congress Programme Committee topic chair for the ESC Congress in the field of arrhythmia from 2018-2020. Since 2020 she has been an executive editor of the European Heart Journal.

Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS is a clinical cardiac electrophysiologist and Associate Professor of Medicine with Tenure at Duke University Medical Center and the Duke Clinical Research Institute. He is the Director of Cardiac Electrophysiology for the Duke University Health System. His focus is on the care of patients with atrial fibrillation and complex arrhythmias, with particular emphasis on catheter ablation, left atrial appendage occlusion, and lead extraction. His research interests include the conduct of clinical trials and the assessment of innovative cardiovascular therapeutics for the care of patients with heart rhythm disorders. He has served as the principal investigator and/or study chair for several clinical trials and registries, including NOVA AF, RESTORE SR, ORBIT AF I & II, Get With The Guidelines-AFIB, and GENETIC AF, the first trial of pharmacogenetic guided rhythm control. He also serves the Chairman of the Heart Rhythm Society’s Atrial Fibrillation Centers of Excellence Task Force. He is an associate editor for the American Heart Journal and serves on the editorial board of several journals, including Heart Rhythm, theEuropean Heart Journal, JACC: Clinical Electrophysiology, Circulation: Arrhythmia & Electrophysiology and the Journal of Cardiac Electrophysiology. Dr. Piccini has more than 425 publications in the field of heart rhythm medicine and has been the recipient of several teaching and mentorship awards.

Dr. Dhanunjaya Lakkireddy is a board-certified, fellowship-trained cardiologist specializing in electrophysiology and the Medical Director for the Kansas City Heart Rhythm Institute at HCA Midwest Health. Dr. Lakkireddy is affiliated with the HCA Midwest Health network of hospitals located throughout the Kansas City, Mo and Overland Park, Kan. metro areas. With more than 15 years of experience, he has specialized clinical expertise and interests in electrophysiology, complex arrhythmia management (atrial fibrillation, atrial flutter, ventricular tachycardia, supraventricular tachycardia), heart ablation, left atrial appendage closure; ablation, pacemaker and other device implantation and management, cardiac resynchronization therapy & pulmonary artery pressure sensors in heart failure, premature ventricular contractions, syncope, adult congenital and inherited cardiac rhythm disorders (Long QT, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, Brugada syndrome) and myocarditis. He is a Professor of Medicine at the University of Missouri, Columbia and a renowned leader in electrophysiology research and education.

Dr. Lakkireddy is the recipient of numerous professional honors and awards, including a Professional Leader of the Year from the Asian Chamber of Commerce, Prevention Magazine Integrative Medicine Award and Ingram’s Heroes in Health Care Award. Many of his accolades have centered on his extensive clinical research activity. He continues to serve as the principal investigator for clinical trials and studies around the world. He has published more than 350 articles on his cutting-edge research in the field of electrophysiology. Additionally, Dr. Lakkireddy serves as Editor-in-Chief for the Journal of Atrial Fibrillation, Deputy Editor for the Journal of Interventional Electrophysiology and Editorial Board member and reviewer for more than 30 scientfic publications including the American Heart Journal, American Journal of Cardiology, Clinical Cardiology, Heart Rhythm Journal, and the Journal of Interventional Cardiac Electrophysiology. He was the former Governor of the Kansas American College of Cardiology, and is currently the Chairman of the ACC Electrophysiology Council and a member of the Program Committee in the Heart Rhythm Society. He is a featured speaker in several national and international cardiovascular symposia.

Dr. Jacqueline Saw is an Interventional Cardiologist at Vancouver General Hospital and St Paul’s Hospital, Clinical Professor of Medicine at UBC, and Program Director of the VGH Interventional Cardiology Fellowship Program. She served as the Head of VGH Cardiology Clinical Trials Research.

Dr. Saw is an international key opinion leader in spontaneous coronary artery dissection (SCAD) and left atrial appendage closure (LAAC). She is the PI of the Canadian SCAD Study, Canadian SCAD Genetic Study, CanSCAD3000 Study, PRYME, NACAD, and SAFER-SCAD studies. She is a Michael Smith Foundation Health Research Professional Investigator for SCAD research.

She is an active physician proctor for LAAC with WATCHMAN and ACP/Amulet devices, the PI of multiple LAAC studies (ASAP-TOO, Canadian WATCHMAN Registry, Canadian ACP/Amulet Registry), and the Chair for the SCAI Expert Consensus Statement on Transcatheter LAAC.

Dr. Saw is an associate editor of JACC Cardiovascular Intervention. She has authored over 320 peer-reviewed publications, including scientific research manuscripts, review papers, book chapters and abstracts, and is the primary editor of three textbooks on LAAC and carotid artery stenting. She has given over 550 scientific talks internationally.

Dr. Mylotte is a Senior Lecturer and Consultant Cardiologist at the University Hospital and National University of Ireland Galway. He undertook fellowship training in interventional and structural cardiology at the Institut Cardiovasculaire de Paris in Massy, France, and at McGill University in Montreal, Canada. He completed postdoctoral theses in both basic (RCSI, Dublin, Ireland) and clinical sciences (Erasmus University, Rotterdam, The Netherlands). Dr. Mylotte has published more than 150 articles in peer-reviewed journals and is a Deputy Editor of EuroIntervention. He is a course co-director for PCR-London Valve, PCR CIT Chengdu Valve, and AICT-Aisa PCR. Dr. Mylotte’s research interests include development of novel therapies for valvular and structural heart disease.

Dr. Molly Szerlip received her medical degree and completed her residency at Tulane University in New Orleans, Louisiana. She was a Major in the US Army where she was Vice Chief of the Internal Medicine Clinic at Eisenhower Army Medical Center in Augusta, Georgia. She completed her fellowship in cardiology at Medical College of Georgia and her interventional cardiology fellowship at William Beaumont Hospital in Royal Oak, Michigan. Dr. Szerlip joined the Baylor Scott and White Heart Hospital in Plano in 2013. She is the Medical Director of the Percutaneous Valve Program, which oversees both the large TAVR program as well as the percutaneous mitral and tricuspid programs. She helped start and grow the Structural Heart Fellowship Program in 2015 and in 2019 she helped develop and became the Program Director for the newly formed Cardiology Fellowship. She will also oversee the Interventional, EP and Heart Failure sub-specialties.

Prior to arriving at the Heart Hospital, she was faculty at the University of Arizona. Dr. Szerlip helped develop the structural heart program which was highlighted by the first percutaneous aortic valve program in Tucson. She was also Director of the Coronary Hybrid Revascularization program where she worked closely with the cardiothoracic surgeons in the combination of stenting the coronaries and robotic bypass. At the University of Arizona she developed her expertise in structural heart disease, which has led her to lecture nationally and internationally at major meetings and to become a rising figurehead in major studies pertaining to percutaneous valve treatments.

In 2015, Dr. Szerlip was chosen by The Society for Cardiovascular Angiography and Interventions (SCAI) to participate in the Emerging Leader Mentorship (ELM) Program. As a member of this highly select group of physicians, Dr. Szerlip participated in a two-year mentorship program designed to further develop her skills as a leader in medicine, ambassador for her specialty, and advocate for her patients. She is currently the Chairmen of SCAI publication committee and is a member of the SCAI Board of trustees.

Her specialty and interests in interventional cardiology include structural heart disease, complex coronary disease and cardiogenic shock.

Dr Anita Asgar is an Interventional Cardiologist working at the Montreal Heart Institute since 2009.  Originally from Newfoundland, Dr. Asgar completed her medical school and Internal Medicine Residency at Memorial University (1995-2002), and Cardiology training at Dalhousie University. She then completed a two-year fellowship in Interventional Cardiology at the Institut de Cardiologie de Montreal, followed by a fellowship in Structural and Congenital Intervention at the Royal Brompton Hospital in London, England as well as a fellowship in Cardiac Magnetic Resonance Imaging. She has a master’s degree in Biomedical Sciences from the Universite de Montreal with a focus in cost-effectiveness of transcatheter technology.

Dr. Anita Asgar is a full-time staff Interventional Cardiologist at the Montreal Heart Institute, and Associate Professor of Medicine at the Universite de Montreal. She specializes in transcatheter valve interventions, congenital interventions and cardiac MRI.  Dr. Asgar was Co-Chair of the Canadian TAVR Guidelines and chairs the Working Group for Transcatheter Valve Therapy Quality Indicators in Canada. She has led the publication of two national quality reports for TAVR in Canada in 2016 and 2019 and was the Co-Chair of the Canadian Position statement for TAVR in 2019. She is the lead cardiologist for the transcatheter mitral/tricuspid valve program at the Montreal Heart Institute. Her research interests include the treatment and management of valvular heart disease and cost-effectiveness analysis and she is currently the Director of Transcatheter Valve Therapy Research at the Montreal Heart Institute.

Dr. Paul Sorajja is an interventional cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, where he is the Director of the Center for Valve and Structural Heart Disease, and is the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation. He received his medical degree from Mayo Medical School and completed his Internal Medicine Residency and Cardiology Fellowship at the Mayo Graduate School of Medicine. During 1998-99, he was a clinical research fellow in myopathy at St. George’s Hospital in London, UK. Dr. Sorajja joined the Mayo Clinic staff in 2006, achieving the rank of Professor of Medicine in 2012. In 2013, Dr. Sorajja joined the Minneapolis Heart Institute.

Dr. Sorajja’s clinical practice specializes in interventional cardiology, with a focus on catheter-based therapy of valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the U.S. for a patient with native mitral regurgitation in 2015, and has the highest worldwide experience with TMVR. Dr. Sorajja has published over 200 manuscripts and book chapters, with expertise in cardiac hemodynamics, clinical education, hypertrophic cardiomyopathy, and percutaneous therapy of structural heart disease. He has served in leadership positions for multiple national societies, and is a founding Board member of the Cardiovascular Innovations Foundation.  Dr. Sorajja has been an editor-in-chief for numerous textbooks on cardiac catheterization. He has served as a program director for interventional cardiology fellowships, and has received awards for his expertise in medical education.  In 2017, he received the Robert G. Hauser Award for Leadership Excellence in Innovation from the Minneapolis Heart Institute Foundation. Dr. Sorajja is also highly active in intellectual property development.

Dr. Adam Greenbaum has dedicated his career to advancing medicine through clinical research, putting his leading-edge ideas into practice through patient care, and teaching future generations of doctors through resident and fellow education. He has received numerous patient care and teaching awards and is recognized as a clinical expert in the field of structural heart disease. He has also authored numerous research articles in the specialty of cardiovascular disease, especially structural heart disease.

Patients with structural heart problems have new treatment options because of the truly novel minimally invasive techniques Dr. Greenbaum developed. His transcatheter methods and approaches to valvular heart disease bring new hope to patients with no other options.
Before joining Emory University in 2018 as a Co-director of the Structural Heart and Valve Center, Dr. Greenbaum served at the Henry Ford Heart and Vascular Institute in Detroit, Michigan for 19 years. He held positions there as Co-director of the Center for Structural Heart Disease, Director of the Cardiac Catheterization Laboratory and Director of the Interventional Fellowship Program. He is board certified in general and interventional cardiology and is a Fellow of the American College of Cardiology, the American Heart Association and the Society for Cardiovascular Angiography and Interventions.

Dr. Greenbaum graduated from the New York University School of Medicine in New York, NY. He completed his internal medicine training at the University of Michigan in Ann Arbor, MI and his general and interventional cardiology training at Duke University in Durham, NC.

Dr. Kendra Grubb is an Associate Professor of Surgery and Medicine and serves as the Surgical Director of the Structural Heart and Valve Center at Emory University.   Dr. Grubb is a champion for women’s heart disease and is dedicated to improving the lives of all patients, both male and female, through innovation and by building collaborative teams to promote a patient-centered approach to the treatment of cardiovascular disease.

Dr. Grubb attended the University of Southern California, where she received her MD degree from the Keck School of Medicine and her Master of Health Administration from the Sol Price School of Public Policy. She completed her general surgery residency at the University of Illinois at Chicago in 2010, her fellowship in cardiothoracic surgery at the University of Virginia in Charlottesville in 2012, and her fellowship in interventional cardiology and transcatheter therapies at New York Presbyterian/Columbia University Medical Center in 2013.

Dr. Hahn is Professor of Medicine at Columbia University Irving Medical Center in New York, and Chief Scientific Officer of the Cardiovascular Research Foundation Echo Core Lab. She is the Director of Interventional Echocardiography at the Columbia Structural and Valve Center since 2011. She is an active member of the American Society of Echocardiography (numerous prior committees, past BOD, Scientific Sessions Planning Committee) as well as the American College of Cardiology (member of the Competency Management Committee, past Scientific Sessions Planning Committee/Valvular Heart Disease Topic Coordinator). She has published over 200 articles on Echocardiography and was on the writing committees for multiple American Society of Echocardiography Recommendations/Guidelines and a co-author of the updated Valve Academic Research Consortium (VARC-3) and Paravalvular Leak Academic Research Consortium.   She participates and a co-investigator in over 10 trials at Columbia University.    

Dr. Marta Sitges completed her degree in Medicine and Surgery at the Universitat Autònoma de Barcelona in 1993. Since that time, she has stayed at the Hospital Clínic (Barcelona, Spain) as resident, research fellow and then as a permanent staff cardiologist. She also visited the Cardiovascular Imaging Center at the Cleveland Clinic Foundation, USA, during a 1-year fellowship. In 2003, she obtained her PhD degree from the Universitat de Barcelona, Spain, focusing on the effects of hormonal replacement therapy on vascular reactivity. Her main research interests currently include cardiac imaging, resynchronization therapy, valvular heart disease, and cardiac remodeling. She has published more than 250 peer reviewed papers (Hindex 50), presented more than 300 lectures in National and International meetings, written 36 book chapters, received 60 grants, including H2020 projects and prizes (16 as Principal Investigator), and directed 12 completed and 3 ongoing PhD theses. She is also referee for most of the principal cardiovascular journals and Professor of Medicine at the University of Barcelona. She was certified in “Management of Integrated Health Systems” by the business school ESADE in 2012. Dr. Sitges is the coordinator of the Sports Cardiology Group at Hospital Clinic and director of the program of Sports Cardiology at FC Barcelona since 2009. She has been staff cardiologist since 2001 at the Cardiovascular Institute in Hospital Clinic in Barcelona, Head of Cardiac Imaging from 2013 to 2015 and Director of the Cardiovascular Institute since October 2015.